GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Cyclically Adjusted PB Ratio

Redhill Biopharma (Redhill Biopharma) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Redhill Biopharma's current share price is $0.433. Redhill Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $311.32. Redhill Biopharma's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Redhill Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Redhill Biopharma's highest Cyclically Adjusted PB Ratio was 1.19. The lowest was 0.01. And the median was 0.14.

RDHL's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.76
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Redhill Biopharma's adjusted book value per share data for the three months ended in Jun. 2023 was $0.881. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $311.32 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Redhill Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Redhill Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Cyclically Adjusted PB Ratio Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.33 0.02 -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.02 0.01 - -

Competitive Comparison of Redhill Biopharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Cyclically Adjusted PB Ratio falls into.



Redhill Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Redhill Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.433/311.32
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Redhill Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.881/128.7287*128.7287
=0.881

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201309 88.764 98.790 115.664
201312 74.068 98.326 96.970
201403 169.589 99.695 218.979
201406 154.158 100.560 197.341
201409 136.266 100.428 174.666
201412 113.836 99.070 147.916
201503 136.396 99.621 176.249
201506 869.742 100.684 1,112.003
201509 2,084.194 100.392 2,672.493
201512 189.046 99.792 243.863
201603 1,728.122 100.470 2,214.174
201606 1,540.736 101.688 1,950.444
201609 127.036 101.861 160.544
201612 147.030 101.863 185.809
201703 1,382.411 102.862 1,730.042
201706 113.733 103.349 141.663
201709 79.062 104.136 97.734
201712 84.737 104.011 104.874
201803 68.012 105.290 83.153
201806 48.549 106.317 58.783
201809 62.473 106.507 75.508
201812 72.172 105.998 87.649
201903 59.044 107.251 70.868
201906 44.985 108.070 53.585
201909 32.219 108.329 38.286
201912 68.050 108.420 80.797
202003 24.751 108.902 29.257
202006 36.982 108.767 43.769
202009 30.684 109.815 35.969
202012 14.442 109.897 16.917
202103 45.463 111.754 52.368
202106 25.323 114.631 28.437
202109 8.816 115.734 9.806
202112 6.775 117.630 7.414
202203 -3.976 121.301 -4.219
202206 -7.483 125.017 -7.705
202209 -28.748 125.227 -29.552
202212 -20.773 125.222 -21.355
202303 0.741 127.348 0.749
202306 0.881 128.729 0.881

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Redhill Biopharma  (NAS:RDHL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Redhill Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.